title: Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies.
abstract: The last couple of years have seen the beginning of a new era in the treatment of metastatic melanoma. This disease is typically characterized by its poor prognosis and limited choice of therapy. Two mechanistically diverse classes of agents - BRAF inhibitors and immune modulators - have demonstrated an overall survival benefit. Along with their significant clinical benefits, there are also unique adverse events (AEs) related to these agents. While most of the AEs are mild and easily managed with supportive treatment, others require more aggressive management strategies. Education of all members of the multidisciplinary care team and awareness of these toxicities are crucial in order to optimize patient outcomes. The landscape of melanoma is continually evolving as ongoing trials are evaluating monotherapy and combination options. While these regimens continue to show promise for the future, understanding and managing toxicities of currently available therapies is required.
authors.affiliation: Centre Hospitalier Universitaire de Québec, Hôtel-Dieu de Québec; Melanoma and Skin Cancer Clinic, Quebec City, QC, Canada; Department of Dermatologic Oncology, British Columbia Cancer Agency, and Department of Dermatology and Science, University of British Columbia, Vancouver, BC, Canada; Division of Medical Oncology/Hematology, Odette Cancer Centre, Toronto, ON, Canada.
authors.forename: Joel
authors.initials: J
authors.lastname: Claveau
authors.forename: Vincent
authors.initials: V
authors.lastname: Ho
authors.forename: Teresa
authors.initials: T
authors.lastname: Petrella
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D010348:Patient Care Team / Q000458:organization & administration; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012871:Skin Diseases / Q000139:chemically induced / Q000517:prevention & control*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf